Compare RSSS & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSSS | VANI |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.7M | 95.8M |
| IPO Year | N/A | N/A |
| Metric | RSSS | VANI |
|---|---|---|
| Price | $2.51 | $1.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $5.00 | $4.00 |
| AVG Volume (30 Days) | 68.3K | ★ 563.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.92 | N/A |
| Revenue Next Year | $7.09 | N/A |
| P/E Ratio | $21.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.32 | $0.91 |
| 52 Week High | $4.12 | $1.92 |
| Indicator | RSSS | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 33.64 | 46.23 |
| Support Level | $2.41 | $1.16 |
| Resistance Level | $2.62 | $1.31 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 18.87 | 27.27 |
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.